Vertex Lifts 2026 Revenue Outlook to $13.2B on CF Drug Strength
VRTX sits 30% above its 52-week low of $362.5.
Summary
Vertex raised its 2026 revenue guidance to a range of $13.1 billion to $13.2 billion, reflecting strong cystic fibrosis demand. Q2 revenue of $3.33 billion beat estimates by $100 million, driven by Alyftrek's ramp to $573.6 million in sales. Trikafta missed expectations at $2.50 billion, but the overall CF franchise remains robust. The outlook excludes the pending $10 billion Crinetics acquisition, which is expected to close in Q3 and will add endocrine disorder assets. This follows the July 6 announcement of the Crinetics deal and the recent FDA approval of Casgevy for pediatric sickle cell disease. The raised guidance signals confidence in the core CF business ahead of the transformative acquisition.
Updates
· SEC 8-K — Vertex reported Q2 revenue of $3.33 billion, up 12% year over year, and raised full-year 2026 revenue guidance to $13.1 billion to $13.2 billion from $12.95 billion to $13.1 billion. The company reiterated expense guidance and expects the Crinetics acquisition to close in Q3 2026.
At the time of this announcement, VRTX was trading at $471.49 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $119.5B. The 52-week trading range was $362.50 to $533.67. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Reuters.